A Randomized, Double-Blind, Placebo-controlled Phase III Study of DE-766 with Cisplatin/Vinorellbine plus Concurrent Thoracic Radiotherapy in Patients with Unresectable Locally Advanced Squamous Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 24 May 2016
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 29 Apr 2014 Planned End Date changed to 30 Jun 2021, according to JapicCTI.
- 25 Apr 2014 Status changed from recruiting to discontinued, according to a Daiichi Sankyo media release.
- 02 May 2013 New trial record